Sonoma Pharmaceuticals (SNOA) vs Beyond Air (XAIR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Sonoma Pharmaceuticals is the larger company by market cap ($3.7 million vs $2.6 million), about 1.4 times the size, while Beyond Air is growing revenue faster (+107.3% vs +36.7%). Sonoma Pharmaceuticals converts more of its revenue into profit, with a net margin of -16.3% versus -433.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | SNOA | XAIR |
|---|---|---|
| Share price | $0.722 | $1.54 |
| Market cap | $3.65M | $2.57M |
| 1-day change | -10.83% | -10.47% |
| EPS (TTM) | $-0.90 | $-39.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $19.53M | $7.68M |
| Revenue growth (YoY) | +36.68% | +107.26% |
| Net income (latest FY) | $-3.17M | $-33.25M |
| Gross margin | 37.97% | 3.28% |
| Operating margin | -12.60% | -378.23% |
| Net margin | -16.26% | -432.99% |
| 52-week high | $3.95 | $53.20 |
| 52-week low | $0.72 | $1.53 |
| Distance from 52-week high | -81.72% | -97.11% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +1198.70% |
| Average volume | 61.96K | 228.73K |
| Shares outstanding | 5.06M | 1.67M |
| Employees | 10 | 54 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Sonoma Pharmaceuticals is more profitable, keeping -16.3 cents of every revenue dollar as net income versus -433.0 cents for Beyond Air.
- Beyond Air grew revenue faster in its latest fiscal year (+107.26% vs +36.68%).
About Sonoma Pharmaceuticals
SNOA stock →Sonoma Pharmaceuticals, Inc. develops and produces stabilized hypochlorous acid (HOCl) products for wound and eye care, oral and nasal care, podiatry, animal health care, and dermatological conditions in the United States, Europe, Asia, Latin America, and internationally.
Health Care · Medical/Dental Instruments · 10 employees
About Beyond Air
XAIR stock →Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company.
Health Care · Medical/Dental Instruments · 54 employees
SNOA vs XAIR FAQ
Which is bigger, Sonoma Pharmaceuticals or Beyond Air?
Sonoma Pharmaceuticals (SNOA) is larger, with a market capitalization of $3.65M compared with $2.57M for Beyond Air (XAIR).
Are Sonoma Pharmaceuticals and Beyond Air in the same industry?
Yes. Both are classified in the Medical/Dental Instruments industry within the Health Care sector.